Olatoyosi Odenike to Proto-Oncogene Proteins c-kit
This is a "connection" page, showing publications Olatoyosi Odenike has written about Proto-Oncogene Proteins c-kit.
Connection Strength
0.206
-
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.
Score: 0.112
-
Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol. 2011 Apr; 38(2):196-214.
Score: 0.094